Matches in Wikidata for { <http://www.wikidata.org/entity/Q90088613> ?p ?o ?g. }
- Q90088613 description "artículu científicu espublizáu en marzu de 2020" @default.
- Q90088613 description "im März 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q90088613 description "scientific article published on 02 March 2020" @default.
- Q90088613 description "wetenschappelijk artikel" @default.
- Q90088613 description "наукова стаття, опублікована 2 березня 2020" @default.
- Q90088613 name "The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients" @default.
- Q90088613 name "The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients" @default.
- Q90088613 type Item @default.
- Q90088613 label "The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients" @default.
- Q90088613 label "The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients" @default.
- Q90088613 prefLabel "The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients" @default.
- Q90088613 prefLabel "The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients" @default.
- Q90088613 P1433 Q90088613-AF181D73-CF8C-4E83-918D-906BA9BF7CE1 @default.
- Q90088613 P1476 Q90088613-0A6C1F77-9B5B-44B6-9071-F27342C02AA7 @default.
- Q90088613 P2093 Q90088613-066C4F90-C7E6-4F43-84C6-011D16EFF964 @default.
- Q90088613 P2093 Q90088613-5561EA08-7230-4BB7-8F66-1AB0DB54F653 @default.
- Q90088613 P2093 Q90088613-59B0110B-363C-4ABB-9890-8C9A30B676B8 @default.
- Q90088613 P2093 Q90088613-5E020F9B-0C8D-447F-96CC-693A03E5AFBF @default.
- Q90088613 P2093 Q90088613-623E97DB-77AA-45D5-9760-EECAFCFA4E9E @default.
- Q90088613 P2093 Q90088613-6AA8AD0E-9BCD-4CA2-8AE7-5D9175CDF09C @default.
- Q90088613 P2093 Q90088613-7338D7AA-CBAE-43C0-A7A4-1C3804AF187B @default.
- Q90088613 P2093 Q90088613-830BB913-703C-45DA-A32C-B602120E0E9B @default.
- Q90088613 P2093 Q90088613-861613AF-D32B-42D7-A087-F41F3BC81A44 @default.
- Q90088613 P2093 Q90088613-AE331938-CF9E-4AA9-9CC6-B7BCFFA218E5 @default.
- Q90088613 P2093 Q90088613-B1382BE8-228A-4B1D-BC32-4C3BC41237A0 @default.
- Q90088613 P2093 Q90088613-C08405A2-66E2-41B0-B9B6-A195670D2731 @default.
- Q90088613 P2093 Q90088613-C2253E87-3519-443B-901B-32347228227E @default.
- Q90088613 P2093 Q90088613-C474006C-6D22-422C-B576-4D185E4EBB71 @default.
- Q90088613 P2093 Q90088613-E5893028-677F-46B0-A290-9816C962358F @default.
- Q90088613 P2093 Q90088613-EBD1935C-50DE-40BA-8CA2-62BF2C166308 @default.
- Q90088613 P2860 Q90088613-0D84E1B8-E600-4C88-8545-28195F38D05C @default.
- Q90088613 P2860 Q90088613-0E832390-5B15-4401-BC87-D2CF571836C6 @default.
- Q90088613 P2860 Q90088613-172AAE37-02FD-4ED6-BABB-91EC6BAB4A16 @default.
- Q90088613 P2860 Q90088613-18DE2BE0-8290-4589-9748-A4CA2950752F @default.
- Q90088613 P2860 Q90088613-1C29C2ED-78FF-41DD-A0A1-75A9422563A0 @default.
- Q90088613 P2860 Q90088613-23F6053D-5357-47E2-AE4A-30BC94121423 @default.
- Q90088613 P2860 Q90088613-33757504-51E4-4CB6-9DD9-6FE97C73FF81 @default.
- Q90088613 P2860 Q90088613-375A9560-CD98-4D3D-B8C9-107E3543330C @default.
- Q90088613 P2860 Q90088613-4B354278-F2B7-453A-A861-692928B48366 @default.
- Q90088613 P2860 Q90088613-54ABFCFD-DAC9-4840-9896-15CF42B6F93F @default.
- Q90088613 P2860 Q90088613-54F2B7E8-F05C-49C3-87C4-9265C378BCCE @default.
- Q90088613 P2860 Q90088613-578AE2C2-1D6A-4E68-B69B-9CB22C448E95 @default.
- Q90088613 P2860 Q90088613-5A5062DB-AA93-4532-BC51-E8BFC7A2A347 @default.
- Q90088613 P2860 Q90088613-6150A4C4-FF6B-4B75-96C7-610654067EFE @default.
- Q90088613 P2860 Q90088613-7556541E-A382-4444-A8F5-F74ABFB5CB4A @default.
- Q90088613 P2860 Q90088613-8FFCEE78-717E-4A52-BF3E-933E50750E89 @default.
- Q90088613 P2860 Q90088613-9B5F1470-C75F-46D9-9BA3-6B1F5E73C406 @default.
- Q90088613 P2860 Q90088613-9E28ABF8-CE88-4E0F-929C-5D246885E4E8 @default.
- Q90088613 P2860 Q90088613-A8246E2F-6AA8-44F8-9FA7-6F678D012C15 @default.
- Q90088613 P2860 Q90088613-A98BE2F9-F5C6-4397-A867-FA4C409D97AA @default.
- Q90088613 P2860 Q90088613-BEBA0865-91F1-46DF-BFEC-9DEAF2B47C35 @default.
- Q90088613 P2860 Q90088613-D450E52E-5BF2-4C79-B4B3-6D5552E0FC46 @default.
- Q90088613 P2860 Q90088613-DC28B6E6-0310-49E5-96C6-1A92AE2B8961 @default.
- Q90088613 P2860 Q90088613-E68386E3-25F7-45C0-BA1A-F14A053BB263 @default.
- Q90088613 P2860 Q90088613-E913D177-07BE-46B1-891D-15D3EB559E1E @default.
- Q90088613 P2860 Q90088613-EFC8B497-B8C9-4665-8E7B-813451218390 @default.
- Q90088613 P2860 Q90088613-F993C33E-36BB-48A7-9881-D486912281EE @default.
- Q90088613 P31 Q90088613-08447E84-1F65-4D18-AEB3-4C50DE08EC38 @default.
- Q90088613 P356 Q90088613-EAEF03DA-9DAF-4E4A-B06D-D6FC7AC69246 @default.
- Q90088613 P577 Q90088613-3A0412A4-4708-43D5-A678-A7720482627F @default.
- Q90088613 P698 Q90088613-E9D4FEB8-7492-4DBA-9F46-A4A8F01D032D @default.
- Q90088613 P921 Q90088613-00789D98-4C5C-45C5-A4B3-0B495C296C49 @default.
- Q90088613 P921 Q90088613-DFB0DDF5-FCE5-42F3-85A0-3B8A36F8CC8C @default.
- Q90088613 P356 J.UROLONC.2020.02.005 @default.
- Q90088613 P698 32139290 @default.
- Q90088613 P1433 Q2113446 @default.
- Q90088613 P1476 "The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients" @default.
- Q90088613 P2093 "Eiji Kikuchi" @default.
- Q90088613 P2093 "Kazuhiro Matsumoto" @default.
- Q90088613 P2093 "Keisuke Shigeta" @default.
- Q90088613 P2093 "Koichiro Ogihara" @default.
- Q90088613 P2093 "Masafumi Oyama" @default.
- Q90088613 P2093 "Masashi Niwakawa" @default.
- Q90088613 P2093 "Mototsugu Oya" @default.
- Q90088613 P2093 "Ryo Yamashita" @default.
- Q90088613 P2093 "Ryuichi Mizuno" @default.
- Q90088613 P2093 "Ryuto Nakazawa" @default.
- Q90088613 P2093 "Satoshi Hara" @default.
- Q90088613 P2093 "Seiya Hattori" @default.
- Q90088613 P2093 "Shunsuke Yoshimine" @default.
- Q90088613 P2093 "Suguru Shirotake" @default.
- Q90088613 P2093 "Takashi Okabe" @default.
- Q90088613 P2093 "Takeshi Masuda" @default.
- Q90088613 P2860 Q27022482 @default.
- Q90088613 P2860 Q27860852 @default.
- Q90088613 P2860 Q28131668 @default.
- Q90088613 P2860 Q28139358 @default.
- Q90088613 P2860 Q34188723 @default.
- Q90088613 P2860 Q38721230 @default.
- Q90088613 P2860 Q38763346 @default.
- Q90088613 P2860 Q38936555 @default.
- Q90088613 P2860 Q39084242 @default.
- Q90088613 P2860 Q41979947 @default.
- Q90088613 P2860 Q42682360 @default.
- Q90088613 P2860 Q47419988 @default.
- Q90088613 P2860 Q47717093 @default.
- Q90088613 P2860 Q48104435 @default.
- Q90088613 P2860 Q50198682 @default.
- Q90088613 P2860 Q53062494 @default.
- Q90088613 P2860 Q55031823 @default.